These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19581185)

  • 1. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Ratiograstim (biocompatible filgrastim)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):177-8. PubMed ID: 19581185
    [No Abstract]   [Full Text] [Related]  

  • 2. Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?
    Ferretti G; Papaldo P
    J Clin Oncol; 2006 Dec; 24(35):5615-6; author reply 5616. PubMed ID: 17158552
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of pegfilgrastim and filgrastim.
    Grigg AP
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):176, 179-80. PubMed ID: 16166989
    [No Abstract]   [Full Text] [Related]  

  • 4. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Vectibix (panitumumab)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):175-6. PubMed ID: 19581184
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving the management of chemotherapy-induced neutropenia.
    Crawford J
    J Support Oncol; 2004; 2(2 Suppl 2):36-9. PubMed ID: 16108418
    [No Abstract]   [Full Text] [Related]  

  • 6. NCCN guidelines advocate wider use of colony-stimulating factor.
    McNeil C
    J Natl Cancer Inst; 2005 May; 97(10):710-1. PubMed ID: 15900037
    [No Abstract]   [Full Text] [Related]  

  • 7. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
    Pikó B;
    Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
    [No Abstract]   [Full Text] [Related]  

  • 8. Mathematical model for G-CSF administration after chemotherapy.
    Foley C; Mackey MC
    J Theor Biol; 2009 Mar; 257(1):27-44. PubMed ID: 19007795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology statement regarding the use of outside services to prepare or administer chemotherapy drugs.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 May; 21(9):1882-3. PubMed ID: 12668649
    [No Abstract]   [Full Text] [Related]  

  • 10. [Febrile neutropenia (FN) in children with acute myeloid leukemia].
    Ivanova LF; Dmitrieva NV; Popa AV; Bagirova NS; Durnov LA
    Vopr Onkol; 2001; 47(4):493-5. PubMed ID: 11710300
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filgrastim and pegfilgrastim use in patients with neutropenia.
    Quirion E
    Clin J Oncol Nurs; 2009 Jun; 13(3):324-8. PubMed ID: 19502191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on neutropenia and myeloid growth factors.
    Crawford J
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):27-46. PubMed ID: 17550054
    [No Abstract]   [Full Text] [Related]  

  • 14. Taming three high-risk chemotherapy complications.
    Held-Warmkessel J
    Nursing; 2011 Nov; 41(11):30-7. PubMed ID: 21986902
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.
    Wang J; An L; Chen S; Ouyang J; Zhou R; Chen B; Yang Y
    Acta Haematol; 2009; 121(4):223-6. PubMed ID: 19546524
    [No Abstract]   [Full Text] [Related]  

  • 16. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withholding antibiotics from patients with febrile neutropenia.
    Lyman GH
    J Clin Oncol; 2006 Mar; 24(7):1221-2; author reply 1222-3. PubMed ID: 16505444
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hematopoietic growth factors in iatrogenic neutropenia in oncology].
    Klastersky J
    Rev Mal Respir; 1995; 12(5):407-8. PubMed ID: 8560070
    [No Abstract]   [Full Text] [Related]  

  • 19. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What you need to know about fever and neutropenia.
    Syrop J
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):2 p following 40. PubMed ID: 18154210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.